Spero Therapeutics Provides Corporate Update and 2024
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in...
Source: globenewswire.com
Lora Grassilli News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lora Grassilli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lora Grassilli Today - Breaking & Trending Today
Spero Therapeutics Announces First Patient, First Visit for
$95 million in development milestones payable over two years, as part of GSK license agreement...
Source: globenewswire.com
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
CAMBRIDGE, Mass., Jan. 02, 2024 -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high...
Source: marketscreener.com
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating ...
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas
Source: eagletribune.com
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET...
Source: marketscreener.com